Skip to content

Psilocybin research published in 2017

Page 2 of 3: studies 21 to 40 of 44, newest first. Back to the psilocybin overview

Studies

NATURALIZING PSYCHEDELIC SPIRITUALITY

Zygon: Journal of Religion and Science August 18, 2017 Chris Letheby 18 citations

A pressing philosophical problem is how to respond to the existential, anxiety and disenchantment resulting from a naturalistic worldview that eschews transcendent foundations for meaning and value. This problem is becoming more urgent as the popularization of neuroscientific findings renders a disenchanted conception of human beings ever more vivid, compelling, and widespread. I argue that the...

DOI: 10.1111/zygo.12353 (opens in new tab) Psilocybin Spirituality Disenchantment Transformative learning +7

Enzymatische Synthese von Psilocybin

Angewandte Chemie August 1, 2017 Janis Fricke, Felix Blei, Dirk Hoffmeister 26 citations

Abstract Psilocybin ist der psychotrope, vom Tryptamin abgeleitete Naturstoff der Psilocybe‐Fruchtkörper, der so genannten “Zauberpilze”. Obwohl dessen Struktur seit 60 Jahren bekannt ist, blieb die enzymatische Grundlage ihrer Biosynthese ungeklärt. Wir charakterisierten vier Psilocybin‐Biosyntheseenzyme, nämlich i) PsiD, welches zu einer neuen Klasse pilzlicher l ‐Tryptophan‐Decarboxylasen...

Enzymatic Synthesis of Psilocybin

Angewandte Chemie International Edition August 1, 2017 Janis Fricke, Felix Blei, Dirk Hoffmeister 210 citations

Abstract Psilocybin is the psychotropic tryptamine‐derived natural product of Psilocybe carpophores, the so‐called “magic mushrooms”. Although its structure has been known for 60 years, the enzymatic basis of its biosynthesis has remained obscure. We characterized four psilocybin biosynthesis enzymes, namely i) PsiD, which represents a new class of fungal l ‐tryptophan decarboxylases, ii) PsiK,...

Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow

Neuroimage July 12, 2017 Candace R. Lewis, Katrin H. Preller, Rainer Kraehenmann et al. 105 citations

Psilocybin, the active compound in psychedelic mushrooms, is an agonist of various serotonin receptors. Seminal psilocybin positron emission tomography (PET) research suggested regional increases in glucose metabolism in frontal cortex (hyperfrontality). However, a recent arterial spin labeling (ASL) study suggests psilocybin may lead to hypo-perfusion in various brain regions. In this...

DOI: 10.1016/j.neuroimage.2017.07.020 (opens in new tab) Psilocybin Insula Cerebral blood flow Anterior cingulate cortex +5

LSD treatment in Scandinavia: emphasizing indications and short-term treatment outcomes of 151 patients in Denmark

Nordic Journal of Psychiatry July 5, 2017 Jens Knud Larsen 15 citations

Despite the significant limitations to a retrospective design, this database warrants caution in mental health patients. The use of LSD and psilocybin in mental health patients may be associated with serious short- and long-term side effects. Until further trials with rigorous designs have cleared these drugs of their potential harms, their clinical utility in these groups of patients has not...

DOI: 10.1080/08039488.2017.1336251 (opens in new tab) Psilocybin Danish Hallucinogen Retrospective cohort study +2

Psychotherapie mit adjuvanter Gabe von serotonergen psychoaktiven Substanzen – Möglichkeiten und Hindernisse

Fortschritte der Neurologie · Psychiatrie July 1, 2017 Tomislav Majić, Henrik Jungaberle, Timo Torsten Schmidt et al. 10 citations

Zusammenfassung Hintergrund Der Einsatz von serotonergen Halluzinogenen (Psychedelika) wie Lysergsäure-Diethylamid (LSD) und Psilocybin und Entaktogenen wie 3,4-Methylendioxymethamphetamin (MDMA) im Rahmen von Psychotherapie ist in den letzten Jahren wieder zunehmend ins Licht des wissenschaftlichen Interesses gerückt. Die vorliegende Arbeit fasst die aktuelle Evidenz zur substanzunterstützten...

Potential Therapeutic Effects of Psilocybin.

Neurotherapeutics July 1, 2017 Matthew W. Johnson, Roland R. Griffiths 301 citations

Psilocybin and other 5-hydroxytryptamine2A agonist classic psychedelics have been used for centuries as sacraments within indigenous cultures. In the mid-twentieth century they were a focus within psychiatry as both probes of brain function and experimental therapeutics. By the late 1960s and early 1970s these scientific inquires fell out of favor because classic psychedelics were being used...

DOI: 10.1007/s13311-017-0542-y (opens in new tab) Full text (opens in new tab) Psilocybin: psilocybin Psychological conditions Mental health concerns Patient well-being +8

Developing Guidelines and Competencies for the Training of Psychedelic Therapists

Journal of Humanistic Psychology June 29, 2017 Janis Phelps 215 citations

Research since the 1950s has shown that psychedelic-assisted psychotherapy has had significant positive effects in reductions of specific clinical symptoms and increases in quality of life as measured on a variety of indices. The intensity of focus on evidence-based outcomes, however, has resulted in a paucity of active discussions and research on the core competencies of the therapists...

DOI: 10.1177/0022167817711304 (opens in new tab) Psilocybin Context archaeology Psychotherapist Neglect +2

Lifetime experience with (classic) psychedelics predicts pro-environmental behavior through an increase in nature relatedness

Journal of Psychopharmacology June 20, 2017 Matthias Forstmann, Christina Sagioglou 153 citations

In a large-scale ( N = 1487) general population online study, we investigated the relationship between past experience with classic psychedelic substances (e.g. LSD, psilocybin, mescaline), nature relatedness, and ecological behavior (e.g. saving water, recycling). Using structural equation modeling we found that experience with classic psychedelics uniquely predicted self-reported engagement...

Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression

Journal of Humanistic Psychology June 19, 2017 Rosalind Watts, Camilla Day, Jacob Krzanowski et al. 582 citations

Objective: To identify patients’ perceptions of the value of psilocybin as a treatment for depression. Method: Twenty patients enrolled in an open-label trial of psilocybin for treatment-resistant depression participated in a semistructured interview at 6-month follow-up. Thematic analysis was used to identify patients’ experiences of the treatment and how it compared with previous treatments....

Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications

Current Neuropharmacology June 19, 2017 Rainer Kraehenmann 90 citations

The broad overlap between dreaming and psychedelic states supports the notion that psychedelics acutely induce dreamlike subjective experiences which may have long-term beneficial effects on psychosocial functioning and well-being. Future clinical studies should examine how therapeutic outcome is related to the acute dreamlike effects of psychedelics.

Effect of Psilocybin on Empathy and Moral Decision-Making

The International Journal of Neuropsychopharmacology June 14, 2017 Thomas Pokorny, Katrin H. Preller, Michael Kometer et al. 202 citations

Background: Impaired empathic abilities lead to severe negative social consequences and influence the development and treatment of several psychiatric disorders. Furthermore, empathy has been shown to play a crucial role in moral and prosocial behavior. Although the serotonin system has been implicated in modulating empathy and moral behavior, the relative contribution of the various serotonin...

Cancer at the Dinner Table: Experiences of Psilocybin-Assisted Psychotherapy for the Treatment of Cancer-Related Distress

Journal of Humanistic Psychology June 14, 2017 Thomas Cody Swift, Alexander Belser, Gabrielle Agin-Liebes et al. 187 citations

Recent randomized controlled trials of psilocybin-assisted psychotherapy for patients with cancer suggest that this treatment results in large-magnitude reductions in anxiety and depression as well as improvements in attitudes toward disease progression and death, quality of life, and spirituality. To better understand these findings, we sought to identify psychological mechanisms of action...

Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders

Journal of Psychoactive Drugs May 8, 2017 Kelan Thomas, Benjamin Malcolm, Dan Lastra 77 citations

Recent research suggests that functional connectivity changes may be involved in the pathophysiology of psychiatric disorders. Hyperconnectivity in the default mode network has been associated with psychopathology, but psychedelic serotonin agonists like psilocybin may profoundly disrupt these dysfunctional neural network circuits and provide a novel treatment for psychiatric disorders. We have...

Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis

Journal of Humanistic Psychology April 28, 2017 Alexander Belser, Gabrielle Agin-Liebes, Thomas Cody Swift et al. 305 citations

The psychological mechanisms of action involved in psilocybin-assisted psychotherapy are not yet well understood. Despite a resurgence of quantitative research regarding psilocybin, the current study is the first qualitative study of participant experiences in psilocybin-assisted psychotherapy. Semistructured interviews were carried out with 13 adult participants aged 22 to 69 years ( M = 50...

DOI: 10.1177/0022167817706884 (opens in new tab) Psilocybin Interpretative phenomenological analysis Psychotherapist Feeling +3

Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin

Scientific Reports April 19, 2017 Michael Schartner, Robin Carhart-Harris, Adam B. Barrett et al. 450 citations

Abstract What is the level of consciousness of the psychedelic state? Empirically, measures of neural signal diversity such as entropy and Lempel-Ziv (LZ) complexity score higher for wakeful rest than for states with lower conscious level like propofol-induced anesthesia. Here we compute these measures for spontaneous magnetoencephalographic (MEG) signals from humans during altered states of...

Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults

Clinical Pharmacokinetics March 28, 2017 Randall Brown, Christopher R. Nicholas, Nicholas V. Cozzi et al. 189 citations

IntroductionPsilocybin is a psychedelic tryptamine that has shown promise in recent clinical trials for the treatment of depression and substance use disorders. This open-label study of the pharmacokinetics of psilocybin was performed to describe the pharmacokinetics and safety profile of psilocybin in sequential, escalating oral doses of 0.3, 0.45, and 0.6 mg/kg in 12 healthy...

DOI: 10.1007/s40262-017-0540-6 (opens in new tab) Psilocybin Pharmacokinetics Pharmacology Urine +2

No clinically relevant effects in children after accidental ingestion of Panaeolina foenisecii (lawn mower's mushroom).

Clinical Toxicology March 2017 Katharina M Schenk-Jaeger, Katharina E Hofer-Lentner, Bettina Plenert et al.

Panaeolina foenisecii is one of the most common and widely distributed lawn mushrooms in Europe and North America, and frequently involved in accidental mushroom ingestion, mainly in children. Nevertheless, there is contradictory information regarding the toxicity profile of P. foenisecii in the literature. Objective of the study was to assess clinical effects with particular attention on...

Designer Drugs 2.0

Clinical Pharmacology & Therapeutics January 13, 2017 Marilyn A. Huestis, Rachel F. Tyndale 12 citations

This “Designer Drugs 2.0” issue of Clinical Pharmacology & Therapeutics focuses on novel psychoactive substances, primarily cannabinoids and cathinones, and the repurposing of established psychoactive compounds (e.g., modafinil, psilocybin, lysergic acid diethylamide, and 3,4‐methylenedioxymethamphetamine) that simultaneously offer new pharmacotherapies and pose serious health problems. Novel...